Skip to main content
Top
Published in: AIDS and Behavior 6/2013

Open Access 01-07-2013 | Original Paper

Peer-Education Intervention to Reduce Injection Risk Behaviors Benefits High-Risk Young Injection Drug Users: A Latent Transition Analysis of the CIDUS 3/DUIT Study

Authors: Mary E. Mackesy-Amiti, Lorna Finnegan, Lawrence J. Ouellet, Elizabeth T. Golub, Holly Hagan, Sharon M. Hudson, Mary H. Latka, Richard S. Garfein

Published in: AIDS and Behavior | Issue 6/2013

Login to get access

Abstract

We analyzed data from a large randomized HIV/HCV prevention intervention trial with young injection drug users (IDUs) conducted in five U.S. cities. The trial compared a peer education intervention (PEI) with a time-matched, attention control group. Applying categorical latent variable analysis (mixture modeling) to baseline injection risk behavior data, we identified four distinct classes of injection-related HIV/HCV risk: low risk, non-syringe equipment-sharing, moderate-risk syringe-sharing, and high-risk syringe-sharing. The trial participation rate did not vary across classes. We conducted a latent transition analysis using trial baseline and 6-month follow-up data, to test the effect of the intervention on transitions to the low-risk class at follow-up. Adjusting for gender, age, and race/ethnicity, a significant intervention effect was found only for the high-risk class. Young IDU who exhibited high-risk behavior at baseline were 90 % more likely to be in the low-risk class at follow-up after the PEI intervention, compared to the control group.
Literature
1.
go back to reference Santibanez S, Garfein R, Swartzendruber A, Purcell D, Paxton L, Greenberg A. Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States. J Urban Health. 2006;83(1):86–100.PubMedCrossRef Santibanez S, Garfein R, Swartzendruber A, Purcell D, Paxton L, Greenberg A. Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States. J Urban Health. 2006;83(1):86–100.PubMedCrossRef
3.
go back to reference Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436–41.PubMed Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436–41.PubMed
4.
go back to reference Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of Hepatitis B and C. Washington DC.: The National Academies Press; 2010. Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of Hepatitis B and C. Washington DC.: The National Academies Press; 2010.
5.
go back to reference Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. J Infect Dis. 2000;182(6):1588–94.PubMedCrossRef Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. J Infect Dis. 2000;182(6):1588–94.PubMedCrossRef
6.
go back to reference Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, et al. Prevalence of Hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clin Infect Dis. 2008;46(12):1852–8.PubMedCrossRef Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, et al. Prevalence of Hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clin Infect Dis. 2008;46(12):1852–8.PubMedCrossRef
7.
go back to reference Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86(5):655–61.PubMedCrossRef Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86(5):655–61.PubMedCrossRef
8.
go back to reference Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149(3):203–13.PubMedCrossRef Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149(3):203–13.PubMedCrossRef
10.
go back to reference Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart ML, Montaner JSG, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59–65.PubMedCrossRef Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart ML, Montaner JSG, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59–65.PubMedCrossRef
11.
go back to reference Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645–53.PubMedCrossRef Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645–53.PubMedCrossRef
12.
go back to reference Thiede H, Hagan H, Campbell JV, Strathdee SA, Bailey SL, Hudson SM, et al. Prevalence and correlates of indirect sharing practices among young adult injection drug users in five U.S. cities. Drug Alcohol Depend. 2007;91(Suppl. 1):S39–47.PubMedCrossRef Thiede H, Hagan H, Campbell JV, Strathdee SA, Bailey SL, Hudson SM, et al. Prevalence and correlates of indirect sharing practices among young adult injection drug users in five U.S. cities. Drug Alcohol Depend. 2007;91(Suppl. 1):S39–47.PubMedCrossRef
13.
go back to reference Centers for Disease Control and Prevention. HIV-associated behaviors among injecting drug users—23 cities, United States, May 2005–February 2006. Morb Mortal Wkl Rep. 2009;58(13):329–32. Centers for Disease Control and Prevention. HIV-associated behaviors among injecting drug users—23 cities, United States, May 2005–February 2006. Morb Mortal Wkl Rep. 2009;58(13):329–32.
14.
go back to reference Bluthenthal RN, Anderson R, Flynn NM, Kral AH. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug Alcohol Depend. 2007;89(2–3):214–22.PubMedCrossRef Bluthenthal RN, Anderson R, Flynn NM, Kral AH. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug Alcohol Depend. 2007;89(2–3):214–22.PubMedCrossRef
15.
go back to reference Huo D, Ouellet LJ. Needle exchange and sexual risk behaviors among a cohort of injection drug users in Chicago, Illinois. Sex Transm Dis. 2009;36(1):35–40.PubMedCrossRef Huo D, Ouellet LJ. Needle exchange and sexual risk behaviors among a cohort of injection drug users in Chicago, Illinois. Sex Transm Dis. 2009;36(1):35–40.PubMedCrossRef
16.
go back to reference Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005;19(Suppl. 3):S20–5.PubMedCrossRef Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005;19(Suppl. 3):S20–5.PubMedCrossRef
17.
go back to reference Coyle SL, Needle RH, Normand J. Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep. 1998;113(Suppl. 1):19–30.PubMed Coyle SL, Needle RH, Normand J. Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep. 1998;113(Suppl. 1):19–30.PubMed
18.
go back to reference Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6–7):777–813.PubMedCrossRef Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6–7):777–813.PubMedCrossRef
19.
go back to reference Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15(11):1329–41.PubMedCrossRef Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15(11):1329–41.PubMedCrossRef
20.
go back to reference Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000;14(5):605–11.PubMedCrossRef Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000;14(5):605–11.PubMedCrossRef
21.
go back to reference Marshall BDL, Wood E. Toward a comprehensive approach to HIV prevention for people who use drugs. J Acquir Immune Defic Syndr. 2010;55(Suppl. 1):S23–6.PubMedCrossRef Marshall BDL, Wood E. Toward a comprehensive approach to HIV prevention for people who use drugs. J Acquir Immune Defic Syndr. 2010;55(Suppl. 1):S23–6.PubMedCrossRef
22.
go back to reference Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59(1):17–31.PubMedCrossRef Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59(1):17–31.PubMedCrossRef
23.
go back to reference Booth RE, Kwiatkowski CF, Stephens RC. Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. J Psychoact Drugs. 1998;30(3):269–78.CrossRef Booth RE, Kwiatkowski CF, Stephens RC. Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. J Psychoact Drugs. 1998;30(3):269–78.CrossRef
24.
go back to reference Gibson DR, Lovelle-Drache J, Young M, Hudes ES, Sorensen JL. Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: final results of randomized trials of counseling with and without HIV testing. AIDS Behav. 1999;3(1):3–12. Gibson DR, Lovelle-Drache J, Young M, Hudes ES, Sorensen JL. Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: final results of randomized trials of counseling with and without HIV testing. AIDS Behav. 1999;3(1):3–12.
25.
go back to reference Meader N, Ryan L, Des Jarlais DC, Pilling S. Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database Syst Rev. 2010; (1). doi:10.1002/14651858.CD007192.pub2. Meader N, Ryan L, Des Jarlais DC, Pilling S. Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database Syst Rev. 2010; (1). doi:10.​1002/​14651858.​CD007192.​pub2.
26.
go back to reference Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. Int J Drug Policy. 2012;23(3):176–84.PubMedCrossRef Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. Int J Drug Policy. 2012;23(3):176–84.PubMedCrossRef
27.
go back to reference Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22(4):332–9.PubMedCrossRef Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22(4):332–9.PubMedCrossRef
28.
go back to reference Latka MH, Hagan H, Kapadia F, Golub ET, Bonner S, Campbell JV, et al. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. Am J Public Health. 2008;98(5):853–61.PubMedCrossRef Latka MH, Hagan H, Kapadia F, Golub ET, Bonner S, Campbell JV, et al. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. Am J Public Health. 2008;98(5):853–61.PubMedCrossRef
29.
go back to reference Tobin KE, Kuramoto SJ, Davey-Rothwell MA, Latkin CA. The STEP into Action study: a peer-based, personal risk network-focused HIV prevention intervention with injection drug users in Baltimore, Maryland. Addiction. 2011;106(2):366–75.PubMedCrossRef Tobin KE, Kuramoto SJ, Davey-Rothwell MA, Latkin CA. The STEP into Action study: a peer-based, personal risk network-focused HIV prevention intervention with injection drug users in Baltimore, Maryland. Addiction. 2011;106(2):366–75.PubMedCrossRef
30.
go back to reference Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS. 2007;21(14):1923–32.PubMedCrossRef Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS. 2007;21(14):1923–32.PubMedCrossRef
31.
go back to reference Mackesy-Amiti ME, Ouellet LJ, Golub ET, Hudson S, Hagan H, Garfein RS. Predictors and correlates of reduced frequency or cessation of injection drug use during a randomized HIV prevention intervention trial. Addiction. 2011;106(3):601–8.PubMedCrossRef Mackesy-Amiti ME, Ouellet LJ, Golub ET, Hudson S, Hagan H, Garfein RS. Predictors and correlates of reduced frequency or cessation of injection drug use during a randomized HIV prevention intervention trial. Addiction. 2011;106(3):601–8.PubMedCrossRef
32.
go back to reference Muthén B. Latent variable modeling in heterogeneous populations. Psychometrika. 1989;54(4):557–85.CrossRef Muthén B. Latent variable modeling in heterogeneous populations. Psychometrika. 1989;54(4):557–85.CrossRef
33.
go back to reference McCutcheon AL. Latent class analysis. Newbury Park: Sage; 1987. McCutcheon AL. Latent class analysis. Newbury Park: Sage; 1987.
34.
go back to reference Collins LM, Wugalter SE. Latent class models for stage-sequential dynamic latent-variables. Multivar Behav Res. 1992;27(1):131–57.CrossRef Collins LM, Wugalter SE. Latent class models for stage-sequential dynamic latent-variables. Multivar Behav Res. 1992;27(1):131–57.CrossRef
35.
go back to reference Lanza ST, Flaherty BP, Collins LM. Latent class and latent transition analysis. Handbook of psychology. Hoboken: Wiley; 2003. Lanza ST, Flaherty BP, Collins LM. Latent class and latent transition analysis. Handbook of psychology. Hoboken: Wiley; 2003.
36.
go back to reference Collins LM, Graham JW, Rousculp SS, Fidler PL, Pan J, Hansen WB. Latent transition analysis and how it can address prevention research questions. In: Collins LM, Seitz LA, editors. Advances in data analysis for prevention intervention research. Rockville: U.S. Department of Health and Human Services; 1994. Collins LM, Graham JW, Rousculp SS, Fidler PL, Pan J, Hansen WB. Latent transition analysis and how it can address prevention research questions. In: Collins LM, Seitz LA, editors. Advances in data analysis for prevention intervention research. Rockville: U.S. Department of Health and Human Services; 1994.
37.
go back to reference Garfein RS, Swartzendruber A, Ouellet LJ, Kapadia F, Hudson SM, Thiede H, et al. Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend. 2007;91(Suppl. 1):S4–17.PubMedCrossRef Garfein RS, Swartzendruber A, Ouellet LJ, Kapadia F, Hudson SM, Thiede H, et al. Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend. 2007;91(Suppl. 1):S4–17.PubMedCrossRef
38.
go back to reference Purcell DW, Garfein RS, Latka MH, Thiede H, Hudson S, Bonner S, et al. Development, description, and acceptability of a small-group, behavioral intervention to prevent HIV and hepatitis C virus infections among young adult injection drug users. Drug Alcohol Depend. 2007;91(Suppl. 1):S73–80.PubMedCrossRef Purcell DW, Garfein RS, Latka MH, Thiede H, Hudson S, Bonner S, et al. Development, description, and acceptability of a small-group, behavioral intervention to prevent HIV and hepatitis C virus infections among young adult injection drug users. Drug Alcohol Depend. 2007;91(Suppl. 1):S73–80.PubMedCrossRef
39.
go back to reference MPlus [computer program]. Muthén & Muthén; Ver. 6.1, 2010. MPlus [computer program]. Muthén & Muthén; Ver. 6.1, 2010.
41.
go back to reference Dickson-Gomez J, Weeks MR, Convey M, Jianghong L. Social psychological dynamics of enhanced HIV risk reduction among peer interventionists. J Community Psychol. 2011;39(4):369–89.CrossRef Dickson-Gomez J, Weeks MR, Convey M, Jianghong L. Social psychological dynamics of enhanced HIV risk reduction among peer interventionists. J Community Psychol. 2011;39(4):369–89.CrossRef
42.
go back to reference Fisher JD, Misovich S. Social influence and AIDS-preventive behavior. In: Edwards J, Tindale RS, Heath L, Posavac EJ, editors. Social influence processes and prevention. New York: Plenum Press; 1990. p. 39–70. Fisher JD, Misovich S. Social influence and AIDS-preventive behavior. In: Edwards J, Tindale RS, Heath L, Posavac EJ, editors. Social influence processes and prevention. New York: Plenum Press; 1990. p. 39–70.
43.
go back to reference Broadhead RS, Heckathorn DD, Weakliem DL, Anthony DL, Madray H, Mills RJ, et al. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Public Health Rep. 1998;113(Suppl. 1):42–57.PubMed Broadhead RS, Heckathorn DD, Weakliem DL, Anthony DL, Madray H, Mills RJ, et al. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Public Health Rep. 1998;113(Suppl. 1):42–57.PubMed
44.
go back to reference Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to addictive behaviors. Am Psychol. 1992;47(9):1102–14.PubMedCrossRef Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to addictive behaviors. Am Psychol. 1992;47(9):1102–14.PubMedCrossRef
45.
go back to reference Prochaska JO, Redding CA, Harlow LL, Rossi JS, Velicer WF. The transtheoretical model of change and HIV prevention: a review. Health Educ Behav. 1994;21(4):471–86.CrossRef Prochaska JO, Redding CA, Harlow LL, Rossi JS, Velicer WF. The transtheoretical model of change and HIV prevention: a review. Health Educ Behav. 1994;21(4):471–86.CrossRef
46.
go back to reference Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. The Lancet. 2010;376(9737):285–301.CrossRef Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. The Lancet. 2010;376(9737):285–301.CrossRef
47.
go back to reference Huo D, Bailey SL, Garfein RS, Ouellet LJ. Changes in the sharing of drug injection equipment among street-recruited injection drug users in Chicago, Illinois, 1994–1996. Subst Use Misuse. 2005;40(1):63–76.PubMedCrossRef Huo D, Bailey SL, Garfein RS, Ouellet LJ. Changes in the sharing of drug injection equipment among street-recruited injection drug users in Chicago, Illinois, 1994–1996. Subst Use Misuse. 2005;40(1):63–76.PubMedCrossRef
48.
go back to reference Thorpe LE, Bailey SL, Huo D, Monterroso ER, Ouellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997–1999). J Acquir Immune Defic Syndr. 2001;27(1):71–8.PubMed Thorpe LE, Bailey SL, Huo D, Monterroso ER, Ouellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997–1999). J Acquir Immune Defic Syndr. 2001;27(1):71–8.PubMed
49.
go back to reference Sherman SG, Latkin CA, Gielen AC. Social factors related to syringe sharing among injecting partners: a focus on gender. Subst Use Misuse. 2001;36(14):2113–36.PubMedCrossRef Sherman SG, Latkin CA, Gielen AC. Social factors related to syringe sharing among injecting partners: a focus on gender. Subst Use Misuse. 2001;36(14):2113–36.PubMedCrossRef
50.
go back to reference Mandell W, Vlahov D, Latkin C, Oziemkowska M, Cohn S. Correlates of needle sharing among injection-drug users. Am J Public Health. 1994;84(6):920–3.PubMedCrossRef Mandell W, Vlahov D, Latkin C, Oziemkowska M, Cohn S. Correlates of needle sharing among injection-drug users. Am J Public Health. 1994;84(6):920–3.PubMedCrossRef
Metadata
Title
Peer-Education Intervention to Reduce Injection Risk Behaviors Benefits High-Risk Young Injection Drug Users: A Latent Transition Analysis of the CIDUS 3/DUIT Study
Authors
Mary E. Mackesy-Amiti
Lorna Finnegan
Lawrence J. Ouellet
Elizabeth T. Golub
Holly Hagan
Sharon M. Hudson
Mary H. Latka
Richard S. Garfein
Publication date
01-07-2013
Publisher
Springer US
Published in
AIDS and Behavior / Issue 6/2013
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0373-0

Other articles of this Issue 6/2013

AIDS and Behavior 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine